ForPatients
*by Roche*

Systemic Lupus Erythematosus

# A study to compare different doses of fenebrutinib with a “placebo” – in patients with lupus

Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

| Trial Status | Trial Runs In | Trial Identifier |
|---|---|---|
| Completed | 12 Countries | NCT02908100 2016-001039-11 GA30044 |

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

## *Trial Summary:*

This is a study to evaluate the safety and efficacy of GDC-0853 in combination with standard of care therapy in participants with moderate to severe active systemic lupus erythematosus (SLE).

| | |
|---|---|
| **Genentech, Inc.**<br>Sponsor | **Phase 2**<br>Phase |

**NCT02908100 2016-001039-11 GA30044**
Trial Identifiers

## *Eligibility Criteria:*

| Gender | Age | Healthy Volunteers |
|---|---|---|
| All | >= 18 Years & <= 75 Years | No |

Researchers wanted to find out what effect, good or bad, fenebrutinib caused in comparison to a placebo, in patients with systemic lupus erythematosus (lupus). A computer randomly decided which patients joined one of two fenebrutinib dose groups and which patients joined the placebo group. This was a double-blind study where patients and researchers did not know which of the 3 groups each patient belonged to.